Increased leukotriene E4 excretion in systemic mastocytosis

Prostaglandins and Other Lipid Mediators

Volumn 92, Issue 1-4, 2010, Pages 73-76

  Butterfield, Joseph H ^a  

^a MAYO CLINIC   (United States)

Author keywords

Leukotriene E4; Mast cells; Systemic mastocytosis

Indexed keywords

11 EPIPROSTAGLANDIN F2 ALPHA; CREATININE; LEUKOTRIENE E4; N METHYLHISTAMINE; TRYPTASE; HISTAMINE DERIVATIVE; PROSTAGLANDIN F2 ALPHA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME IMMUNOASSAY; HUMAN; MAST CELL DEGRANULATION; PROTEIN EXPRESSION; SYSTEMIC MASTOCYTOSIS; URINALYSIS; URINARY EXCRETION; BLOOD; METABOLISM; URINE;

DINOPROST; HUMANS; LEUKOTRIENE E4; MASTOCYTOSIS, SYSTEMIC; METHYLHISTAMINES; TRYPTASES;

EID: 77952111914     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2010.03.003     Document Type: Article

References (32)

1. Rabinovitch N. Urinary leukotriene E4. Immunol Allergy Clin N Am 27 November (4) (2007) 651-664
2. Jiang Y., Kanaoka Y., Feng C., Nocka K., Rao S., and Boyce J.A. Cutting edge: interleukin 4-dependent mast cell proliferation requires autocrine/intracrine cysteinyl leukotriene-induced signaling. J Immunol 177 September (5) (2006) 2755-2759
3. Paruchuri S., Jiang Y., Feng C., Francis S.A., Plutzky J., and Boyce J.A. Leukotriene E4 activates peroxisome proliferator-activated receptor gamma and induces prostaglandin D2 generation by human mast cells. J Biol Chem 283 June (24) (2008) 16477-16487
4. Lynch K.R., O'Neill G.P., Liu Q., et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399 June (6738) (1999) 789-793
5. Heise C.E., O'Dowd B.F., Figueroa D.J., et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 275 September (39) (2000) 30531-30536
6. Ono E., Taniguchi M., Mita H., et al. Increased urinary leukotriene E4 concentration in patients with eosinophilic pneumonia. Eur Respir J 32 August (2) (2008) 437-442
7. Oh J.W., Shin S.A., and Lee H.B. Urine leukotriene E and eosinophil cationic protein in nasopharyngeal aspiration from young wheezy children. Pediatr Allergy Immunol 16 August (5) (2005) 416-421
8. Hishinuma T., Suzuki N., Aiba S., Tagami H., and Mizugaki M. Increased urinary leukotriene E4 excretion in patients with atopic dermatitis. Br J Dermatol 144 January (1) (2001) 19-23
9. Kim J.H., Tagari P., Griffiths A.M., Ford-Hutchinson A., Smith C., and Sherman P.M. Levels of peptidoleukotriene E4 are elevated in active Crohn's disease. J Pediatr Gastroenterol Nutr 20 May (4) (1995) 403-407
10. Nakamura H., Hishinuma T., Suzuki N., et al. Difference in urinary 11-dehydro TXB2 and LTE4 excretion in patients with rheumatoid arthritis. Prostaglandins Leukot Essent Fatty Acids 65 November-December (5-6) (2001) 301-306
11. Carry M., Korley V., Willerson J.T., Weigelt L., Ford-Hutchinson A.W., and Tagari P. Increased urinary leukotriene excretion in patients with cardiac ischemia: in vivo evidence for 5-lipoxygenase activation. Circulation 85 January (1) (1992) 230-236
12. Allen S.P., Sampson A.P., Piper P.J., Chester A.H., Ohri S.K., and Yacoub M.H. Enhanced excretion of urinary leukotriene E4 in coronary artery disease and after coronary artery bypass surgery. Coron Artery Dis 4 October (10) (1993) 899-904
13. Greally P., Cook A.J., Sampson A.P., et al. Atopic children with cystic fibrosis have increased urinary leukotriene E4 concentrations and more severe pulmonary disease. J Allergy Clin Immunol 93 January (1 Pt 1) (1994) 100-107
14. Peters-Golden M., and Henderson Jr. W.R. Leukotrienes. N Engl J Med 357 November (18) (2007) 1841-1854
15. Uozumi N., Kume K., Nagase T., et al. Role of cytosolic phospholipase A2 in allergic response and parturition. Nature 390 December (6660) (1997) 618-622
16. Luo M., Jones S.M., Phare S.M., Coffey M.J., Peters-Golden M., and Brock T.G. Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523. J Biol Chem 279 October (40) (2004) 41512-41520
17. Valent P., Akin C., Sperr W.R., Horny H.P., and Metcalfe D.D. Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. Hematol Oncol Clin N Am 17 October (5) (2003) 1227-1241
18. Butterfield J.H. Systemic mastocytosis: clinical manifestations and differential diagnosis. Immunol Allergy Clin N Am 26 August (3) (2006) 487-513
19. Castells M. Mast cell mediators in allergic inflammation and mastocytosis. Immunol Allergy Clin N Am 26 August (3) (2006) 465-485
20. Smith C.M., Hawksworth R.J., Thien F.C., Christie P.E., and Lee T.H. Urinary leukotriene E4 in bronchial asthma. Eur Respir J 5 June (6) (1992) 693-699
21. Taylor G.W., Taylor I., Black P., et al. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1 March (8638) (1989) 584-588
22. Steinhilber D. 5-Lipoxygenase: a target for antiinflammatory drugs revisited. Curr Med Chem 6 January (1) (1999) 71-85
23. Kumlin M. Measurement of leukotrienes in humans. Am J Respir Crit Care Med 161 February (2 Pt 2) (2000) S102-S106
24. Berger W., De Chandt M.T., and Cairns C.B. Zileuton: clinical implications of 5-lipoxygenase inhibition in severe airway disease. Int J Clin Pract 61 April (4) (2007) 663-676
25. Riccioni G., Di Ilio C., Conti P., Theoharides T.C., and D'Orazio N. Advances in therapy with antileukotriene drugs. Ann Clin Lab Sci 34 Autumn (4) (2004) 379-387
26. Higashi N., Taniguchi M., Mita H., et al. Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol 113 February (2) (2004) 277-283
27. Steinke J.W., Bradley D., Arango P., et al. Cysteinyl leukotriene expression in chronic hyperplastic sinusitis-nasal polyposis: importance to eosinophilia and asthma. J Allergy Clin Immunol 111 February (2) (2003) 342-349
28. Rackal J.M., and Vender R.B. The treatment of atopic dermatitis and other dermatoses with leukotriene antagonists. Skin Therapy Lett 9 February (2) (2004) 1-5
29. Fee W.H. Irritable bowel syndrome helped by montelukast. Chest 122 October (4) (2002) 1497
30. Tolar J., Tope W.D., and Neglia J.P. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. N Engl J Med 350 February (7) (2004) 735-736
31. Theoharides T.C., Kempuraj D., and Sant G.R. Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. Urology 57 June (6 Suppl. 1) (2001) 47-55
32. Bouchelouche K., Nordling J., Hald T., and Bouchelouche P. The cysteinyl leukotriene D4 receptor antagonist montelukast for the treatment of interstitial cystitis. J Urol 166 November (5) (2001) 1734-1737